Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Development of an HIV-1 integrase genotyping assay for HIV-1 subtype AE.

Liu Y, Margot N, Kitrinos KM, Callebaut C.

J Med Virol. 2019 May;91(5):890-893. doi: 10.1002/jmv.25376. Epub 2018 Dec 21.

PMID:
30548936
2.

Measurement of plasma HIV-1 RNA below the limit of quantification (<20 copies/mL) of commercial assays with the integrase HIV RNA single-copy assay.

Margot N, Koontz D, McCallister S, Mellors JW, Callebaut C.

J Clin Virol. 2018 Nov;108:50-52. doi: 10.1016/j.jcv.2018.09.003. Epub 2018 Sep 10.

PMID:
30240941
3.

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.

Margot N, Cox S, Das M, McCallister S, Miller MD, Callebaut C.

J Clin Virol. 2018 Jun;103:37-42. doi: 10.1016/j.jcv.2018.03.012. Epub 2018 Apr 2.

PMID:
29627709
4.

Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R.

Cox S, Margot N, Miller M, Callebaut C.

AIDS Res Hum Retroviruses. 2018 May;34(5):456-458. doi: 10.1089/AID.2017.0248. Epub 2018 Apr 10.

PMID:
29620930
5.

Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA ≥1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials.

Sax P, DeJesus E, Wohl D, DeMorin J, McColl D, Piontkowsky D, Cohen C, Wang H, White K, Callebaut C, Rhee M, Das M, Quirk E.

Antivir Ther. 2018;23(1):95-99. doi: 10.3851/IMP3187. No abstract available.

PMID:
28799919
6.

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.

Margot NA, Wong P, Kulkarni R, White K, Porter D, Abram ME, Callebaut C, Miller MD.

J Infect Dis. 2017 Mar 15;215(6):920-927. doi: 10.1093/infdis/jix015.

PMID:
28453836
7.

Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.

Cox S, Margot N, Ram R, Johnson A, Miller M, Callebaut C.

Antiviral Res. 2017 Jul;143:22-29. doi: 10.1016/j.antiviral.2017.03.021. Epub 2017 Mar 28.

PMID:
28363735
8.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.

Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350.

PMID:
28282300
9.

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD.

PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017.

10.

Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.

Callebaut C, Liu Y, Babusis D, Ray A, Miller M, Kitrinos K.

PLoS One. 2017 Feb 9;12(2):e0169948. doi: 10.1371/journal.pone.0169948. eCollection 2017.

11.

Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.

Stray KM, Park Y, Babusis D, Callebaut C, Cihlar T, Ray AS, Perron M.

Antiviral Res. 2017 Apr;140:116-120. doi: 10.1016/j.antiviral.2017.01.014. Epub 2017 Jan 26.

PMID:
28131805
13.

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.

Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M, McCallister S.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):193-200. doi: 10.1097/QAI.0000000000001193.

14.

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.

Margot NA, Liu Y, Miller MD, Callebaut C.

Antiviral Res. 2016 Aug;132:50-8. doi: 10.1016/j.antiviral.2016.05.012. Epub 2016 May 18.

PMID:
27208653
15.

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.

Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C.

HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731.

PMID:
26892863
16.

Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.

Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M; GS-US-2,92-01040111 and Study Team.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940.

PMID:
26829661
17.

In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

Callebaut C, Stepan G, Tian Y, Miller MD.

Antimicrob Agents Chemother. 2015 Oct;59(10):5909-16. doi: 10.1128/AAC.01152-15. Epub 2015 Jul 6.

18.

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.

Margot NA, Johnson A, Miller MD, Callebaut C.

Antimicrob Agents Chemother. 2015 Oct;59(10):5917-24. doi: 10.1128/AAC.01151-15. Epub 2015 Jul 6.

19.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team.

Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
25890673
20.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):439-45. doi: 10.1097/QAI.0000000000000618.

PMID:
25867913
21.

A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Abram ME, Tsiang M, White KL, Callebaut C, Miller MD.

Antimicrob Agents Chemother. 2015 Feb;59(2):838-48. doi: 10.1128/AAC.04163-14. Epub 2014 Nov 17.

22.

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.

Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):52-8. doi: 10.1097/QAI.0000000000000225.

PMID:
24872136
23.

Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).

Xu L, Liu H, Hong A, Vivian R, Murray BP, Callebaut C, Choi YC, Lee MS, Chau J, Tsai LK, Stray KM, Strickley RG, Wang J, Tong L, Swaminathan S, Rhodes GR, Desai MC.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):995-9. doi: 10.1016/j.bmcl.2013.12.057. Epub 2013 Dec 21.

PMID:
24412072
24.

Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.

Liu H, Xu L, Hui H, Vivian R, Callebaut C, Murray BP, Hong A, Lee MS, Tsai LK, Chau JK, Stray KM, Cannizzaro C, Choi YC, Rhodes GR, Desai MC.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):989-94. doi: 10.1016/j.bmcl.2013.12.058. Epub 2013 Dec 19.

PMID:
24411125
25.

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW, Yale K.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55. doi: 10.1097/QAI.0b013e3182965d45.

PMID:
23807155
26.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK.

J Infect Dis. 2013 Jul;208(1):32-9. doi: 10.1093/infdis/jit122. Epub 2013 Mar 26.

27.

Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.

Stray KM, Callebaut C, Glass B, Tsai L, Xu L, Müller B, Kräusslich HG, Cihlar T.

J Virol. 2013 Jan;87(1):454-63. doi: 10.1128/JVI.01211-12. Epub 2012 Oct 24.

28.

In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.

Callebaut C, Stray K, Tsai L, Williams M, Yang ZY, Cannizzaro C, Leavitt SA, Liu X, Wang K, Murray BP, Mulato A, Hatada M, Priskich T, Parkin N, Swaminathan S, Lee W, He GX, Xu L, Cihlar T.

Antimicrob Agents Chemother. 2011 Apr;55(4):1366-76. doi: 10.1128/AAC.01183-10. Epub 2011 Jan 18.

29.

GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.

Hruz PW, Yan Q, Tsai L, Koster J, Xu L, Cihlar T, Callebaut C.

Antimicrob Agents Chemother. 2011 Apr;55(4):1377-82. doi: 10.1128/AAC.01184-10. Epub 2011 Jan 18.

30.

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC.

ACS Med Chem Lett. 2010 May 17;1(5):209-13. doi: 10.1021/ml1000257. eCollection 2010 Aug 12.

31.

Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.

Ray AS, Vela JE, Boojamra CG, Zhang L, Hui H, Callebaut C, Stray K, Lin KY, Gao Y, Mackman RL, Cihlar T.

Antimicrob Agents Chemother. 2008 Feb;52(2):648-54. Epub 2007 Dec 3.

32.

Human immunodeficiency virus fusion to dendritic cells declines as cells mature.

Cavrois M, Neidleman J, Kreisberg JF, Fenard D, Callebaut C, Greene WC.

J Virol. 2006 Feb;80(4):1992-9.

33.

Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction.

Ginés S, Mariño M, Mallol J, Canela EI, Morimoto C, Callebaut C, Hovanessian A, Casadó V, Lluis C, Franco R.

Biochem J. 2002 Jan 15;361(Pt 2):203-9.

34.

The anti-HIV pentameric pseudopeptide HB-19 is preferentially taken up in vivo by lymphoid organs where it forms a complex with nucleolin.

Krust B, Vienet R, Cardona A, Rougeot C, Jacotot E, Callebaut C, Guichard G, Briand JP, Grognet JM, Hovanessian AG, Edelman L.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14090-5. Epub 2001 Nov 6.

35.

Inhibition of HIV infection by the cytokine midkine.

Callebaut C, Nisole S, Briand JP, Krust B, Hovanessian AG.

Virology. 2001 Mar 15;281(2):248-64.

37.

The HB-19 pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits attachment of T lymophocyte- and macrophage-tropic HIV to permissive cells.

Nisole S, Krust B, Dam E, Bianco A, Seddiki N, Loaec S, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG.

AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):237-49.

PMID:
10710212
38.

The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans.

Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG.

J Biol Chem. 1999 Sep 24;274(39):27875-84.

39.

The V3 loop-mimicking pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits HIV infection in primary macrophage cultures.

Seddiki N, Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG.

AIDS Res Hum Retroviruses. 1999 Mar 1;15(4):381-90.

PMID:
10082122
40.

Dipeptidyl-peptidase IV-beta--further characterization and comparison to dipeptidyl-peptidase IV activity of CD26.

Blanco J, Nguyen C, Callebaut C, Jacotot E, Krust B, Mazaleyrat JP, Wakselman M, Hovanessian AG.

Eur J Biochem. 1998 Sep 1;256(2):369-78.

41.

Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells.

Callebaut C, Blanco J, Benkirane N, Krust B, Jacotot E, Guichard G, Seddiki N, Svab J, Dam E, Muller S, Briand JP, Hovanessian AG.

J Biol Chem. 1998 Aug 21;273(34):21988-97.

42.

Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+ T cells expressing relatively high levels of CD26.

Callebaut C, Jacotot E, Blanco J, Krust B, Hovanessian AG.

Exp Cell Res. 1998 Jun 15;241(2):352-62.

PMID:
9637777
43.

Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26.

Nguyen C, Blanco J, Mazaleyrat JP, Krust B, Callebaut C, Jacotot E, Hovanessian AG, Wakselman M.

J Med Chem. 1998 Jun 4;41(12):2100-10.

PMID:
9622551
44.

Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles.

Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian AG, Franco R.

J Immunol. 1997 Apr 15;158(8):3721-9.

PMID:
9103436
45.

Pseudopeptide TASP inhibitors of HIV entry bind specifically to a 95-kDa cell surface protein.

Callebaut C, Jacotot E, Krust B, Guichard G, Blanco J, Valenzuela A, Svab J, Muller S, Briand JP, Hovanessian AG.

J Biol Chem. 1997 Mar 14;272(11):7159-66.

46.

HIV-1 envelope glycoproteins-mediated apoptosis is regulated by CD4 dependent and independent mechanisms.

Jacotot E, Krust B, Callebaut C, Laurent-Crawford AG, Blanco J, Hovanessian AG.

Apoptosis. 1997;2(1):47-60.

PMID:
14646564
47.

CD26 as a positive regulator of HIV envelope-glycoprotein induced apoptosis in CD4+ T cells.

Jacotot E, Callebaut C, Blanco J, Rivière Y, Krust B, Hovanessian AG.

Adv Exp Med Biol. 1997;421:207-16. Review.

PMID:
9330699
48.

Further characterization of DPP IV-beta, a novel cell surface expressed protein with dipeptidyl peptidase activity.

Blanco J, Jacotot E, Callebaut C, Krust B, Hovanessian AG.

Adv Exp Med Biol. 1997;421:193-9. Review.

PMID:
9330697
49.

HIV-1 envelope gp120 and viral particles block adenosine deaminase binding to human CD26.

Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian AG, Franco R.

Adv Exp Med Biol. 1997;421:185-92. Review.

PMID:
9330696
50.

The level of CD26 determines the rate of HIV entry in a CD4+ T-cell line.

Callebaut C, Jacotot E, Blanco J, Krust B, Hovanessian AG.

Adv Exp Med Biol. 1997;421:179-84. Review.

PMID:
9330695

Supplemental Content

Loading ...
Support Center